user1asd34123asdsa

About user1asd34123asdsa

This author has not yet filled in any details.
So far user1asd34123asdsa has created 177 blog entries.

Evangelia Christoforatou

2026-11-18T22:49:19+00:00

Evangelia Christoforatou, MD, PhDHead of Echocardiography Dept. - Designated Medical Lead, Pacemakers & ICDs Dept.Heart Rhythm Center & 3rd Department of Cardiology, IASO Hospital Evangelia Christoforatou, MD, PhD, is a Cardiologist and a high-honors doctoral graduate of the National and Kapodistrian University of Athens Medical School. She earned her medical degree from the University of [...]

Evangelia Christoforatou 2026-11-18T22:49:19+00:00

Ranolazine

2026-11-18T22:53:28+00:00

Brand Name: RanexaActive Substance: Ranolazine Indications and Clinical Use Ranolazine is a cardiovascular agent approved for the management of chronic stable angina (chest pain resulting from myocardial ischemia). It is typically administered as an adjunctive/add-on therapy when first-line conventional agents (such as beta-blockers) fail to adequately control symptoms. Off-Label Antiarrhythmic Activity Although not officially indicated [...]

Ranolazine 2026-11-18T22:53:28+00:00

Atropine

2026-11-18T22:54:01+00:00

Trade Name: Atropine Atropine is an intravenously administered medication restricted exclusively to hospital settings. By inhibiting the parasympathetic nervous system, it can increase the heart rate, thereby inducing sinus tachycardia, and concurrently accelerate conduction velocity through the atrioventricular (AV) node. The drug is administered solely via the intravenous route and exhibits a short duration of [...]

Atropine 2026-11-18T22:54:01+00:00

Adenosine

2026-11-18T22:38:45+00:00

Adenosine is an intravenously administered medication with a duration of action lasting only a few seconds. In the field of cardiac arrhythmias, it constitutes the treatment of choice for the immediate termination (cardioversion) of atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT) involving an accessory pathway. Adverse EffectsDue to the ultra-short duration of [...]

Adenosine 2026-11-18T22:38:45+00:00

Digoxin

2026-11-18T22:41:17+00:00

The primary actions of Digoxin are: Increase in ventricular contractility (positive inotropy). Prolongation of atrioventricular (AV) nodal conduction delay, which constitutes its definitive antiarrhythmic mechanism of action. The mechanism of action of digoxin is illustrated in the Figure. The inhibition of the Na⁺/K⁺-ATPase pump by Digoxin leads to an increase in intracellular sodium (Na⁺). This [...]

Digoxin 2026-11-18T22:41:17+00:00

Diltiazem

2026-11-18T22:41:21+00:00

Brand Names: Tildiem, Dipen, Cardil Diltiazem (a Class IV antiarrhythmic agent) belongs to the calcium channel blocker (CCB) class. Along with verapamil, these are the primary agents within this class that exert direct myocardial effects. This distinguishes them from other calcium channel blockers, which predominantly exhibit peripheral vasodilatory activity. Diltiazem can be administered both orally [...]

Diltiazem 2026-11-18T22:41:21+00:00

Verapamil

2026-11-18T22:41:05+00:00

Verapamil (a Class IV antiarrhythmic agent) belongs to the calcium channel blockers. Along with diltiazem, these are the medications within this class that exert direct myocardial effects, in contrast to other calcium channel blockers which primarily exhibit peripheral vasodilatory action. Verapamil can be administered both orally and intravenously. It exerts a more pronounced effect on [...]

Verapamil 2026-11-18T22:41:05+00:00